HTC-C3Homo sapiens (Human)Cancer cell line

Also known as: HTCC3, HTC C3, HTC/C3

🤖 AI SummaryBased on 6 publications

Quick Overview

Human anaplastic thyroid cancer cell line for cancer research.

Detailed Summary

HTC-C3 is a human anaplastic thyroid cancer cell line derived from a patient with anaplastic thyroid carcinoma. It is widely used in research to study the molecular mechanisms of thyroid cancer progression and drug resistance. The cell line exhibits characteristics of aggressive tumor behavior, including rapid proliferation and resistance to various chemotherapeutic agents. Research on HTC-C3 has contributed to understanding the role of genetic alterations, such as DUSP26 amplification and TERT promoter mutations, in cancer development and therapeutic response. These findings are critical for developing targeted therapies and improving patient outcomes.

Research Applications

Molecular mechanisms of thyroid cancer progressionDrug resistance studiesGenetic alterations in cancer developmentTherapeutic response analysis

Key Characteristics

Rapid proliferationResistance to chemotherapeutic agentsDUSP26 amplificationTERT promoter mutations

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1295
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	44
Age Category	Adult
Sex	Female

Disease Information

Disease	Anaplastic thyroid carcinoma
Lineage	Thyroid
Subtype	Anaplastic Thyroid Cancer
OncoTree Code	THAP

DepMap Information

Source Type	DSMZ
Source ID	ACH-001350_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Pro152Leu (c.455C>T)	Unspecified	-	PubMed=21602893
MutationSimple	TERT	c.1-124C>T (c.228C>T) (C228T)	Unspecified	In promoter	from parent cell line Hep-G2
MutationSimple	BRAF	p.Val600Glu (c.1799T>A)	Unspecified	-	PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

11,12

D13S317

10,12

D16S539

9,12

D18S51

14,17

D19S433

D21S11

29,30

D2S1338

17,23

D3S1358

D5S818

11,12

D7S820

11,12

D8S1179

12,14

FGA

21,22

Penta D

Penta E

11,16

TH01

6,7

TPOX

8,9

vWA

14,15

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Fagin J.A., Schweppe R.E.

Clin. Cancer Res. 25:3141-3151(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Ibrahimpasic T., Ghossein R.A., Fagin J.A.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.

Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.

Oncogene 26:1178-1187(2007).

DOI PubMed

Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.

Satake S., Sugawara I., Watanabe M., Takami H.

Cancer Lett. 116:33-39(1997).

DOI PubMed

Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines.

Kitamura N., Yamamoto I., Konishi J., Mori T., Imura H.

Cancer 65:1971-1979(1990).

DOI PubMed

Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.

Cancer Res. 52:5061-5064(1992).

PubMed